secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001558370-25-008415
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony settles Lupin ANDA litigation; generic WAKIX entry delayed to 2030
--------------------------------------------------------------------------

- Lupin receives license to launch generic WAKIX no earlier than January 2030 (July 2030 with pediatric exclusivity).
- Litigation in U.S. District Court for Delaware dismissed as part of the agreement.
- Harmony will continue patent infringement litigation against other ANDA filers seeking generic WAKIX.
- U.S. Patent Office PTAB previously declined to institute reexamination of Harmony's polymorph patent, affirming its validity.
- Harmony is developing next-generation pitolisant formulations with patents extending potential exclusivity to 2044.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025008415/0001558370-25-008415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025008415/hrmy-20250605x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer